Physician profile
Janis Black
NPI 1699721548
$3,251.53
in general payments reported to CMS, 2019-2025
26 companies · $597 in 2025
The $597 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $814 · 2020: $273 · 2021: $319 · 2022: $261 · 2023: $437 · 2024: $550 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,584.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tosoh Bioscience, INC. | $800.00 | 2019 | |
| Novo Nordisk INC | $520.74 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $349.71 | 2020-2025 | |
| Abbvie INC. | $283.81 | 2022-2025 | Vraylar |
| Merck Sharp & Dohme LLC | $215.07 | 2020-2025 | Gardasil 9, Capvaxive, Gardasil |
| Lilly USA, LLC | $161.18 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $159.46 | 2020-2025 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $112.04 | 2020-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $92.26 | 2019-2025 | Airsupra |
| Exact Sciences Corporation | $90.04 | 2023-2025 | Cologuard Collection Kit |
| Almatica Pharma LLC | $75.92 | 2021-2024 | Loreev Xr, Gralise |
| Currax Pharmaceuticals LLC | $46.31 | 2021 | |
| Corium, LLC | $45.12 | 2023-2024 | Azstarys |
| Amarin Pharma, INC. | $38.83 | 2020-2021 | |
| Eisai INC. | $31.02 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $30.60 | 2024 | Auvelity |
| Halozyme INC | $29.10 | 2023 | |
| Vanda Pharmaceuticals INC. | $24.19 | 2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $21.68 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.08 | 2025 | Jardiance |
| Abbott Laboratories | $19.38 | 2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $18.80 | 2023 | Veozah |
| Daiichi Sankyo INC. | $18.48 | 2021 | |
| Penumbra, INC. | $16.54 | 2024 | Indigo System |
| Collegium Pharmaceutical, INC. | $16.23 | 2025 | Jornay Pm |
| Antares Pharma, INC. | $14.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janis Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.